title: Rogletimide
text: # Rogletimide
  
  Rogletimide, also known as pyridoglutethimide, is a medication which was never marketed. It is related in chemical structure to the sedative/hypnotic drug glutethimide, but instead has pharmacological activity as a selective aromatase inhibitor similar to the related drug aminoglutethimide and has no significant sedative-hypnotic effect. This makes it potentially useful in the treatment of breast cancer, and with fewer side effects than aminoglutethimide, but its lower potency caused it to be unsuccessful in clinical trials.
  
  vte Pharmacodynamics of aromatase inhibitors :
  
  | Generation | Medication | Dosage | % $inhibition^a$ | $Class^b$ | $IC_{50}^c$ |
  | - | - | - | - | - | - |
  | First | Testolactone | 250 mg 4x/day p.o. | ? | Type I | ? |
  | First | Testolactone | 100 mg 3x/week i.m. | ? | Type I | ? |
  | First | Rogletimide | 200 mg 2x/day p.o. 400 mg 2x/day p.o. 800 mg 2x/day p.o. | 50.6% 63.5% 73.8% | Type II | ? |
  | First | Aminoglutethimide | 250 mg mg 4x/day p.o. | 90.6% | Type II | 4,500 nM |
  | Second | Formestane | 125 mg 1x/day p.o. 125 mg 2x/day p.o. 250 mg 1x/day p.o. | 72.3% 70.0% 57.3% | Type I | 30 nM |
  | Second | Formestane | 250 mg 1x/2 weeks i.m. 500 mg 1x/2 weeks i.m. 500 mg 1x/1 week i.m. | 84.8% 91.9% 92.5% | Type I | 30 nM |
  | Second | Fadrozole | 1 mg 1x/day p.o. 2 mg 2x/day p.o. | 82.4% 92.6% | Type II | ? |
  | Third | Exemestane | 25 mg 1x/day p.o. | 97.9% | Type I | 15 nM |
  | Third | Anastrozole | 1 mg 1x/day p.o. 10 mg 1x/day p.o. | 96.7–97.3% 98.1% | Type II | 10 nM |
  | Third | Letrozole | 0.5 mg 1x/day p.o. 2.5 mg 1x/day p.o. | 98.4% 98.9%–>99.1% | Type II | 2.5 nM |
  | Footnotes: $^a$ = In postmenopausal women. $^b$ = Type I: Steroidal, irreversible (substrate-binding site). Type II: Nonsteroidal, reversible (binding to and interference with the cytochrome P450 heme moiety). $^c$ = In breast cancer homogenates. Sources: See template. ||||||
  
  ## Synthesis
  
  Base catalyzed alkylation of ethyl 4-pyridylacetate [54401-85-3] (1) with iodoethane gives ethyl 2-(4-pyridyl)butyrate [76766-56-8] (2). Base catalyzed conjugate addition of the carbanion to acrylamide (3) gives (4). The last step is an intramolecular cyclization to rogletimide (5).
  
  